Dr Reddys Laboratories (RDY) Other Non-Current Liabilities (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Other Non-Current Liabilities of $37.0 million for Q1 2026, down 5.13% year-over-year from $39.0 million in Q1 2025, and down 5.13% quarter-over-quarter from $39.0 million in Q1 2025.
Dr Reddys Laboratories (RDY) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Other Non-Current Liabilities history runs 9 years deep, the most recent figure standing at $37.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 5.13% year-over-year to $37.0 million; the TTM figure through Mar 2026 stood at $37.0 million (down 5.13% YoY), while the FY2026 annual figure was $37.0 million, down 5.13% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $37.0 million, down from $39.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $48.0 million in Q1 2024, with the low at $32.0 million in Q1 2022.
- The 5-year median for Other Non-Current Liabilities is $37.0 million (2026), against an average of $38.2 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities jumped 37.14% in 2024, then decreased 18.75% in 2025.
- Dr Reddys Laboratories' Other Non-Current Liabilities stood at $32.0 million in 2022, then increased by 9.38% to $35.0 million in 2023, then surged by 37.14% to $48.0 million in 2024, then fell by 18.75% to $39.0 million in 2025, then dropped by 5.13% to $37.0 million in 2026.
- Business Quant data shows RDY's Other Non-Current Liabilities at $37.0 million in Q1 2026, $39.0 million in Q1 2025, and $48.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.00 Mn |
| Mar 31, 2025 | 39.00 Mn |
| Mar 31, 2024 | 48.00 Mn |
| Mar 31, 2023 | 35.00 Mn |
| Mar 31, 2022 | 32.00 Mn |
| Mar 31, 2021 | 32.00 Mn |
| Mar 31, 2020 | 37.00 Mn |
| Mar 31, 2019 | 1.00 Mn |
| Dec 31, 2009 | -40.00 Mn |
| Sep 30, 2009 | -27.00 Mn |
| Jun 30, 2009 | -19.00 Mn |